Lomond invests $9M in Idwal Therapeutics for Series A preferred units; option for $2M additional

Lomond Therapeutics Holdings, Inc.

Lomond purchased 3.1M Series A Preferred Units of Idwal at $2.90/unit for ~$9.0M; closing occurred Jan 8, 2026.
Idwal formed with MALT-1 program assets from Tegid Therapeutics; total gross proceeds ~$47M from all investors.
Lomond has option to invest additional ~$2.0M on same terms.
Initial managers of Idwal are Lomond's directors: Iain Dukes, Nikolay Savchuk, Carl Gordon, Eddie Wang Rodriguez.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lomond Therapeutics Holdings, Inc. entered into Series A Preferred Unit Purchase Agreement with Idwal Therapeutics, LLC valued at approximately $9.0 million (effective 2026-01-08).

Action: entry
Agreement: equity purchase
Counterparty: Idwal Therapeutics, LLC
Value: approximately $9.0 million
Effective: 2026-01-08

Exact text from the filing

On January 8, 2026, Lomond Therapeutics Holdings, Inc. (the “Company”) entered into a Series A Preferred Unit Purchase Agreement (the “Purchase Agreement”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.85

Lomond Therapeutics Holdings, Inc. entered into Amended and Restated Limited Liability Company Agreement with Idwal Therapeutics, LLC (effective 2026-01-08).

Action: entry
Counterparty: Idwal Therapeutics, LLC
Effective: 2026-01-08

Exact text from the filing

greement”) and related Amended and Restated Limited Liability Company Agreement (the “A&R LLC Agreement”) as an investor in Idwal Therapeutics, LLC (“Idwal”).

View on SEC.gov

Browse all material agreements →

Source: SEC EDGAR

accession 0001213900-26-003908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.